The DOI matches its Crossref record; 197 of the 197 references it cites were found in a registry or an index.
IL-12 Family Cytokines in Cancer and Immunotherapy
Open accessAbstract
The IL-12 family cytokines are a group of unique heterodimeric cytokines that include IL-12, IL-23, IL-27, IL-35 and, most recently, IL-39. Recent studies have solidified the importance of IL-12 cytokines in shaping innate and adaptive immune responses in cancer and identified multipronged roles for distinct IL-12 family members, ranging from effector to regulatory immune functions. These cytokines could serve as promising candidates for the development of immunomodulatory therapeutic approaches. Overall, IL-12 can be considered an effector cytokine and has been found to engage anti-tumor immunity by activating the effector Th1 response, which is required for the activation of cytotoxic T and NK cells and tumor clearance. IL-23 and IL-27 play dual roles in tumor immunity, as they can both activate effector immune responses and promote tumor growth by favoring immune suppression. IL-35 is a potent regulatory cytokine and plays a largely pro-tumorigenic role by inhibiting effector T cells. In this review, we summarize the recent findings on IL-12 family cytokines in the control of tumor growth with an emphasis primarily on immune regulation. We underscore the clinical implications for the use of these cytokines either in the setting of monotherapy or in combination with other conventional therapies for the more effective treatment of malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Collison, L. W., Workman, C. J., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., Cross, R., Sehy, D., Blumberg, R. S., & Vignali, D. A. A. (2007) · Nature · doi:10.1038/nature06306 · Cited by 2,066
Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
Adenoma–linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.-Y., Österreicher, C. H., Hung, K. E., et al. (2012) · Nature · doi:10.1038/nature11465 · Cited by 1,327
IL-12 family cytokines: immunological playmakers
Vignali, D. A. A., & Kuchroo, V. K. (2012) · Nature Immunology · doi:10.1038/ni.2366 · Cited by 1,297
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
The IL-23/IL-17 axis in inflammation
Iwakura, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28508 · Cited by 1,046
IL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018
Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.024 · Cited by 966 · cited 1×
“The activation of anti-tumor immunity by anti-PD1 requires IL-12-mediated crosstalk between T cells and dendritic cells that enables CD8+ T cell-mediated tumor cell killing [22].”
Background
Cited by
Inflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review
Twarowski, B., & Herbet, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076518 · Cited by 412
Mesenchymal stem/stromal cells in cancer therapy
Lan, T., Luo, M., & Wei, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01208-w · Cited by 374
B Cell Function in the Tumor Microenvironment
Downs-Canner, S. M., Meier, J., Vincent, B. G., & Serody, J. S. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101220-015603 · Cited by 287
Liu, M., Hu, S., Yan, N., Popowski, K. D., & Cheng, K. (2024) · Nature Nanotechnology · doi:10.1038/s41565-023-01580-3 · Cited by 277
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Maskalenko, N. A., Zhigarev, D., & Campbell, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00413-7 · Cited by 256
Metadata
- Authors
- Mirlekar, B., & Pylayeva-Gupta, Y.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-01-06
- Volume
- 13
- Issue
- 2
- Pages
- 167
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3119125259
- Cited by
- 295
- References
- 197
- FWCI
- 15.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IL-12 Family Cytokines in Cancer and Immunotherapy. https://app.cochat.ai/papers/10.3390/cancers13020167
- The paper
- Mirlekar, B., & Pylayeva-Gupta, Y. (2021). IL-12 Family Cytokines in Cancer and Immunotherapy. Cancers. https://doi.org/10.3390/cancers13020167
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.